The FDA released draft guidance this week on the development of drugs for treating Fabry disease. Not sure how this may or may not affect Resverlogix's planned Fabry disease trial that is listed on ClinicalTrials.gov. Also, here's an Endpoints News article on this:
Fabry disease: FDA drafts drug development guidance